Keywords: Roche, RoActemra, Systemic juvenile idiopathic arthritis, sJIA, EU

Roche gets EU approval for RoActemra for children with rare form of arthritis

Article | 04 August 2011

Print This

The European Commission has approved the use of Swiss drug major Roche’s (ROG: SIX) RoActemra (tocilizumab) for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in